Medication Cost Trajectory Maps the Injury Curve in PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

A plaintiff's medication cost trajectory over time creates an objective financial map of injury severity, treatment intensity, and recovery progress that directly correlates with the clinical injury curve attorneys need to document for settlement or trial.

Medication Cost Trajectory Maps the Injury Curve in PI Cases

A plaintiff's medication spending pattern over time produces a measurable, objective financial curve that mirrors the clinical injury curve. When monthly prescription costs spike after an accident, remain elevated during active treatment, and gradually taper as recovery progresses, that spending trajectory becomes independent evidence of injury severity and duration that no defense expert can dismiss as subjective.

• The medication cost trajectory provides a second, independently verifiable curve that parallels clinical injury severity documentation
• Spikes in monthly medication spending correlate with treatment escalations, new diagnoses, and surgical events
• A plateau in medication costs suggests a chronic condition, while a gradual decline suggests recovery
• LienScripts tracks every dispensing date and amount, creating a timeline that attorneys can convert into demonstrative exhibits
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, the cost trajectory is often the single clearest visual summary of an injury's arc

Why the Cost Trajectory Matters at Settlement

Insurance adjusters and defense attorneys often challenge subjective pain reports by arguing the plaintiff is exaggerating. The medication cost trajectory is not subjective. It is generated from pharmacy dispensing records with exact dates, exact medications, and exact quantities. When a plaintiff's monthly medication spending jumps from near-zero to a sustained elevated level after an accident and remains there for eighteen months, that financial pattern tells the same story as the medical records but through an entirely different data source.

The trajectory also reveals treatment milestones. A sharp increase in spending may correspond to the initiation of specialty medications after imaging revealed additional pathology. A second spike may correspond to post-surgical medication needs. Each inflection point in the cost curve maps to a clinical event that the attorney can cross-reference with medical records.

How to Read the Trajectory

Acute phase (weeks 1-6): Immediate post-accident prescriptions typically include muscle relaxants, anti-inflammatories, and acute pain medications. The cost curve rises sharply as multiple medications begin simultaneously.

Escalation phase (months 2-6): If the injury does not resolve with first-line treatment, prescribers add medications or switch to more targeted therapies. Gabapentin replaces ibuprofen. A CGRP inhibitor replaces over-the-counter migraine treatment. Each escalation appears as a step-up in the cost trajectory.

Plateau or chronic phase (months 6+): If spending stabilizes at an elevated level, this indicates the plaintiff has reached a maintenance regimen for a condition that has not resolved. This plateau is powerful evidence against the defense argument that the plaintiff recovered months ago.

Taper phase: A gradual reduction in medication costs suggests genuine clinical improvement. This pattern actually strengthens credibility because it shows the plaintiff reduced medications when clinically appropriate rather than maintaining them for litigation purposes.

Building the Exhibit

The most effective way to present the medication cost trajectory is as a line chart with the accident date marked, each medication start/stop date annotated, and corresponding clinical events (imaging, surgery, new diagnoses) overlaid. LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that includes the dispensing timeline needed to construct this exhibit.

Attorneys should request the complete dispensing history from LienScripts and work with their trial graphics team to create the visual. The combination of the financial trajectory and the clinical narrative creates a dual-track presentation that reinforces both the subjective and objective components of the damages case.

The Defense Cannot Challenge the Data Source

Unlike medical records where defense experts may question a treating physician's clinical judgment, pharmacy dispensing records are transactional. Each fill has a date, a National Drug Code, a quantity, and a dispensing pharmacist. The data is generated by the pharmacy's dispensing software at the point of sale. Defense experts can argue about whether a medication was necessary, but they cannot argue that the fill did not happen.

This makes the medication cost trajectory one of the most defensible pieces of objective evidence in a personal injury case. For more on how pharmacy records serve as objective evidence, see Pharmacy Records Are Stronger Than Medical Records Alone and Refill Patterns as Objective Pain Evidence.

Practical Considerations

When reviewing the cost trajectory, attorneys should watch for gaps. A two-month gap in medication fills could be used by the defense to argue recovery. However, as discussed in detail in Refill Gaps Do Not Prove Recovery, gaps often reflect financial barriers, insurance issues, or medication stockpiling rather than clinical improvement. LienScripts' pharmacy lien model eliminates the most common cause of gaps — the inability to pay for prescriptions while the case is pending.

The medication cost trajectory is most powerful when presented alongside the MERIT report, which provides the clinical context for each medication on the timeline. Together, these documents give the adjuster or jury both the "what happened" and the "why it happened" in a format that is difficult to challenge.

Contact LienScripts to discuss how medication cost trajectory documentation can strengthen your demand packages.